Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase II Randomized Trial of Proton Vs. Photon Therapy IMRT For Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
A Phase I/II Study of Nivolumab plus or minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
International Penile Advanced Cancer Trial International Rare Cancers Initiative study
Study Type: Treatment
Phase: III
NCTID: NCT02305654
Principal Investigator:
Elizabeth Wulff-Burchfield
A Phase II, Single-Arm Study of Bempegaldesleukin (Nktr-214) In Combination with Nivolumab In Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients
Study Type: Treatment
Phase: II
NCTID: NCT03785925
Principal Investigator:
Elizabeth Wulff-Burchfield
Laser Ablation of Abnormal Neurological Tissue using Robotic Neuroblate system LAANTERN Prospective Registry
Study Type: Other
Phase: N/A
NCTID: NCT02392078
Principal Investigator:
Patrick Landazuri
Multi-Center Randomized Controlled Phase 2b Clinical Trial To Evaluate The Safety And Efficacy Of Tvi-Brain-1 Combined With Conformal Radiotherapy And Temozolomide Compared To Standard Therapy As A Treatment For Newly Diagnosed O6 -Methylguanine Methyltransferase Negative MGMT Unmethylated Grade 4 Astrocytoma Glioblastoma Multiforme; GBM
Study Type: Treatment
Phase: II
NCTID: NCT05685004
Principal Investigator:
Tolga Tuncer
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
Study Type: Treatment
Phase: II
NCTID: NCT04696029
Principal Investigator:
Kevin Ginn
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib NSC 748727 in Newly Diagnosed or Previously Untreated Low-Grade Glioma LGG Not Associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 NF1
Study Type: Treatment
Phase: III
NCTID: NCT04166409
Principal Investigator:
Keith August
A Phase III Study of Selumetinib NSC 748727, IND 77782 or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas LGGs Lacking BRAFV600E or IDH1 Mutations
Study Type: Treatment
Phase: III
NCTID: NCT04576117
Principal Investigator:
Keith August